RxDoctor Payments Data

Anita Kuruvilla, MD

Internal Medicine · Lufkin, TXNPI 1851377477

Payments from drug & device makers

$866in general payments, 2019–2025

Across 50 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$137
  • Johnson & Johnson$130
  • Lilly USA, LLC$103
  • E.r. Squibb & Sons, L.L.C.$92
  • Novartis$82
  • Dexcom, Inc.$76
  • plus $245 from 8 others

What the payments were for

  • Food & beverage$866100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$866 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$67,234
Medicare patients
141
Services billed
882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban162$163,719
JardianceEmpagliflozin153$158,447
TrulicityDulaglutide35$51,828
JanuviaSitagliptin Phosphate60$50,601
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$36,949
XareltoRivaroxaban38$35,333
FarxigaDapagliflozin Propanediol36$33,304
OzempicSemaglutide12$26,946
TradjentaLinagliptin29$19,729
Lantus SolostarInsulin Glargine,hum.Rec.Anlog97$16,809
Combivent RespimatIpratropium/Albuterol Sulfate15$14,571
CreonLipase/Protease/Amylase22$14,405
EntrestoSacubitril/Valsartan15$9,349
Advair HfaFluticasone Propion/Salmeterol19$8,079
Liothyronine Sodium187$7,742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$137$163,719162 claims
Lilly USA, LLCTrulicity, Humulin 70-30, Humalog$103$56,63368 claims
GSKTrelegy Ellipta, Breo Ellipta$33$43,43969 claims
AstraZenecaFarxiga, Symbicort$36$36,64250 claims
Johnson & JohnsonXarelto$130$35,33338 claims
NovartisEntresto$82$9,34915 claims
Astellas Pharma US IncMyrbetriq$14$6,15813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Lufkin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →